Trailing Twelve Months Revenue Growth: Capricor Therapeutics (CAPR)

Brandmark of capricor.com (CAPR)

The financial stability of Capricor Therapeutics (CAPR) depends on grants and the results of new drug trials. The LTM annual sales growth rate on the GURU.Markets chart reflects revenue dynamics, where the metric level stands at -99.60. The company is currently scaling production to combat Duchenne muscular dystrophy, strictly adhering to bioethical standards and the principles of sustainable laboratory development.

Capricor Therapeutics, Inc. (CAPR): Revenue Growth YoY (Last 12 Months) from 02/11/2024 to 11/18/2026

Capricor Therapeutics Inc. (CAPR) - metric breakdowns and financial figures

- stock price and consensus target price:
- company stock exchange capitalization indicators:
Analysis of all company metrics:Capricor Therapeutics, Inc., CAPR
Mass-produced product of Capricor Therapeutics, Inc.

This indicator measures rolling year revenue dynamics, neutralizing quarterly volatility through a daily recalculation of turnover growth rates. Analyzing the YoY sales growth over the last four quarters on GURU.Markets is critical for Capricor Therapeutics (CAPR), as it reflects the transition from a cost-intensive cell technology development phase to a high-margin commercialization stage for approved therapies.